Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)‘s stock had its “outperform” rating reiterated by research analysts at Leerink Swann in a report released on Wednesday. They currently have a $202.00 price target on the specialty pharmaceutical company’s stock. Leerink Swann’s target price indicates a potential upside of 66.36% from the stock’s current price.
JAZZ has been the topic of a number of other research reports. Janney Montgomery Scott initiated coverage on shares of Jazz Pharmaceuticals PLC in a report on Thursday, August 25th. They set a “neutral” rating on the stock. Zacks Investment Research cut shares of Jazz Pharmaceuticals PLC from a “hold” rating to a “sell” rating in a research note on Wednesday, July 20th. Mizuho reaffirmed a “buy” rating on shares of Jazz Pharmaceuticals PLC in a research note on Monday, June 6th. Piper Jaffray Cos. cut their price objective on shares of Jazz Pharmaceuticals PLC from $188.00 to $178.00 and set an “overweight” rating for the company in a research note on Wednesday, August 10th. Finally, BMO Capital Markets reaffirmed an “outperform” rating and issued a $190.00 price objective on shares of Jazz Pharmaceuticals PLC in a research note on Sunday, July 31st. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and fourteen have given a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $185.25.
Several hedge funds and institutional investors have modified their holdings of JAZZ. Hartford Investment Management Co. acquired a new position in shares of Jazz Pharmaceuticals PLC during the second quarter valued at about $200,000. Financial Architects Inc increased its stake in shares of Jazz Pharmaceuticals PLC by 801.0% in the second quarter. Financial Architects Inc now owns 1,766 shares of the specialty pharmaceutical company’s stock valued at $249,000 after buying an additional 1,570 shares during the period. Springbok Capital Management LLC increased its stake in shares of Jazz Pharmaceuticals PLC by 21.8% in the first quarter. Springbok Capital Management LLC now owns 2,120 shares of the specialty pharmaceutical company’s stock valued at $277,000 after buying an additional 380 shares during the period. 1st Global Advisors Inc. increased its stake in shares of Jazz Pharmaceuticals PLC by 5.0% in the second quarter. 1st Global Advisors Inc. now owns 1,964 shares of the specialty pharmaceutical company’s stock valued at $278,000 after buying an additional 93 shares during the period. Finally, Fisher Asset Management LLC increased its stake in shares of Jazz Pharmaceuticals PLC by 4.8% in the first quarter. Fisher Asset Management LLC now owns 1,949 shares of the specialty pharmaceutical company’s stock valued at $282,000 after buying an additional 90 shares during the period.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/07/jazz-pharmaceuticals-plc-jazz-receives-outperform-rating-from-leerink-swann.html
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) opened at 122.45 on Wednesday. The stock’s 50 day moving average is $138.37 and its 200 day moving average is $139.79. The company has a market cap of $7.41 billion and a P/E ratio of 21.53. Jazz Pharmaceuticals PLC has a 1-year low of $108.50 and a 1-year high of $168.93.
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last posted its earnings results on Tuesday, August 9th. The specialty pharmaceutical company reported $2.63 earnings per share for the quarter, missing the Zacks’ consensus estimate of $2.80 by $0.17. During the same quarter in the previous year, the business earned $2.41 earnings per share. The company had revenue of $381 million for the quarter, compared to analyst estimates of $376.40 million. The company’s revenue for the quarter was up 14.2% compared to the same quarter last year. Equities analysts anticipate that Jazz Pharmaceuticals PLC will post $10.08 earnings per share for the current fiscal year.
In related news, CEO Bruce C. Cozadd sold 1,000 shares of the stock in a transaction dated Tuesday, August 9th. The shares were sold at an average price of $150.00, for a total value of $150,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CMO Karen L. Smith purchased 557 shares of the firm’s stock in a transaction that occurred on Monday, June 13th. The stock was acquired at an average price of $149.61 per share, with a total value of $83,332.77. Following the completion of the purchase, the chief marketing officer now owns 12,994 shares in the company, valued at $1,944,032.34. The disclosure for this purchase can be found here.
Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.
Receive News & Ratings for Jazz Pharmaceuticals PLC Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com’s FREE daily email newsletter.